The USFDA inspected the plant from April 22, 2019 to May 3, 2019. The inspection concluded with 14 observations. There were no repeat observations or data integrity related observations, the drug firm said.
At 09:29 am, the stock was trading 0.38 per cent lower at Rs 303, as compared to 0.89 per cent decline in the S&P BSE Sensex. A combined 849,947 shares have changed hands on the counter on the BSE and NSE so far.